GSK expands respiratory pipeline with novel COPD drug

GSK paid $85 million up front for global rights to a small-interfering RNA therapy discovered and developed by startup Empirico. The pharmaceutical giant said this drug candidate could be used as a monotherapy and as part of drug combinations for treating COPD and other inflammatory respiratory diseases.

Editor's Pick

Top Story GSK's Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD GSK paid $85 million up front for global rights to a small-interfering RNA therapy discovered and developed by startup Empirico. The pharmaceutical giant said this drug candidate could be used as a monotherapy and as part of drug combinations for treating COPD and other inflammatory respiratory diseases. Sponsored Simplifying Complexity: NICU Revenue Code Issues Presented by ProgenyHealth Today, infants are surviving at increasingly younger gestational ages—sometimes as early as 22 weeks. These remarkable advancements, however, come with significant financial implications. NICU claims can easily reach hundreds of thousands of dollars, especially when submitted under a single revenue code level that doesn't reflect the actual intensity or duration of care. To make sense of the clinical and financial implications of NICU care click here.

Featured News

Heard at HLTH 2025: Healthcare Executives Highlight AI, ROI, and Fertility Tech. (Video) [Sponsored] They shared new developments, their views on AI, and what they're doing to disrupt the status quo in healthcare. MedCity Pivot Podcast: A Chat With AWS Chief Medical Officer Rowland Illing Dr. Rowland Illing explained how life science companies and health systems are leveraing AWS HealthLake to transform healthcare. How the Expiration of ACA Tax Credits Will Impact Commercial Insurance, Per a Cigna Exec The expiration of ACA tax credits could drive up premiums across marketplace and commercial insurance plans, a Cigna executive warned. When Healthcare Meets People Where They Are: How PDTs Are Reshaping Mental Health Treatment Here are some key insights to help unlock the viability of PDTs to address unmet needs throughout the healthcare ecosystem — for patients and providers alike — and how to take meaningful steps to improve the health experience.

Video   Virtual OUD Treatment Is Proving Valuable A report from the Peterson Health Technology Institute found that virtual opioid use disorder companies are just as effective as standard in-person treatment — and they can improve retention. For a long time, the OUD treatment community believed that care needed to be delivered in person, noted Caroline Pearson, an executive director at Peterson Health Technology Institute. However, particularly since the pandemic, virtual care has proven to be effective and convenient, especially in place where there aren't many providers.

Resources

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care Choosing the wrong EMR can slow your practice down. This guide helps healthcare teams compare options, avoid costly pitfalls, and choose a platform that improves care, compliance, and patient experience. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe